These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 32687856)

  • 21. Transcriptomic and epigenetic landscape of nimorazole-enhanced radiochemotherapy in head and neck cancer.
    Besso MJ; Bitto V; Koi L; Wijaya Hadiwikarta W; Conde-Lopez C; Euler-Lange R; Bonrouhi M; Schneider K; Linge A; Krause M; Baumann M; Kurth I
    Radiother Oncol; 2024 Oct; 199():110348. PubMed ID: 38823583
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blood and saliva-derived ctDNA is a marker of residual disease after treatment and correlates with recurrence in human papillomavirus-associated head and neck cancer.
    Ferrier ST; Tsering T; Sadeghi N; Zeitouni A; Burnier JV
    Cancer Med; 2023 Aug; 12(15):15777-15787. PubMed ID: 37526056
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor DNA-methylome derived epigenetic fingerprint identifies HPV-negative head and neck patients at risk for locoregional recurrence after postoperative radiochemotherapy.
    Tawk B; Wirkner U; Schwager C; Rein K; Zaoui K; Federspil PA; Adeberg S; Linge A; Ganswindt U; Hess J; Unger K; Tinhofer I; Budach V; Lohaus F; Krause M; Guberina M; Stuschke M; Balermpas P; Rödel C; Grosu AL; Schäfer H; Zips D; Combs SE; Pigorsch S; Zitzelsberger H; Baumeister P; Kirchner T; Bewerunge-Hudler M; Weichert W; Hess J; Herpel E; Belka C; Baumann M; Debus J; Abdollahi A;
    Int J Cancer; 2022 Feb; 150(4):603-616. PubMed ID: 34648658
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
    Eder T; Hess AK; Konschak R; Stromberger C; Jöhrens K; Fleischer V; Hummel M; Balermpas P; von der Grün J; Linge A; Lohaus F; Krause M; Baumann M; Stuschke M; Zips D; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Budach V; Tinhofer I;
    Eur J Cancer; 2019 Jul; 116():67-76. PubMed ID: 31173964
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma circulating tumor DNA as a potential tool for disease monitoring in head and neck cancer.
    Egyud M; Sridhar P; Devaiah A; Yamada E; Saunders S; Ståhlberg A; Filges S; Krzyzanowski PM; Kalatskaya I; Jiao W; Stein LD; Jalisi S; Godfrey TE
    Head Neck; 2019 May; 41(5):1351-1358. PubMed ID: 30554450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating tumour DNA detects somatic variants contributing to spatial and temporal intra-tumoural heterogeneity in head and neck squamous cell carcinoma.
    Payne KFB; Brotherwood P; Suriyanarayanan H; Brooks JM; Batis N; Beggs AD; Gendoo DMA; Mehanna H; Nankivell P
    Front Oncol; 2024; 14():1374816. PubMed ID: 38846976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of gene expressions from squamous cell carcinoma of the head and neck to predict radiochemotherapy-related xerostomia and dysphagia.
    Yahya N; Linge A; Leger K; Maile T; Kemper M; Haim D; Jöhrens K; Troost EGC; Krause M; Löck S
    Acta Oncol; 2022 Jul; 61(7):856-863. PubMed ID: 35657056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Prognostic and Therapeutic Value of the Mutational Profile of Blood and Tumor Tissue in Head and Neck Squamous Cell Carcinoma.
    Wilson HL; D'Agostino RB; Meegalla N; Petro R; Commander S; Topaloglu U; Zhang W; Porosnicu M
    Oncologist; 2021 Feb; 26(2):e279-e289. PubMed ID: 33098199
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The diagnostic value and prospects of gene mutations in circulating tumor DNA for head and neck cancer monitoring.
    Yang X; Xu X; Zhang C; Ji T; Wan T; Liu W
    Oral Oncol; 2022 May; 128():105846. PubMed ID: 35358785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ctDNA as an Adjunct to Posttreatment PET for Head and Neck Cancer Recurrence Risk Assessment.
    Lele SJ; Adilbay D; Lewis E; Pang J; Asarkar AA; Nathan CO
    Otolaryngol Head Neck Surg; 2024 Aug; 171(2):439-444. PubMed ID: 38591659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liquid biopsy in head neck cancer: ready for clinical routine diagnostics?
    Tinhofer I; Staudte S; George S
    Curr Opin Oncol; 2023 May; 35(3):151-157. PubMed ID: 36966499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging.
    Löck S; Perrin R; Seidlitz A; Bandurska-Luque A; Zschaeck S; Zöphel K; Krause M; Steinbach J; Kotzerke J; Zips D; Troost EGC; Baumann M
    Radiother Oncol; 2017 Sep; 124(3):533-540. PubMed ID: 28843726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic biomarkers for the response to the radiosensitizer nimorazole combined with RCTx: a pre-clinical trial in HNSCC xenografts.
    Koi L; Bitto V; Weise C; Möbius L; Linge A; Löck S; Yaromina A; Besso MJ; Valentini C; Pfeifer M; Overgaard J; Zips D; Kurth I; Krause M; Baumann M
    J Transl Med; 2023 Aug; 21(1):576. PubMed ID: 37633930
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current applications and challenges of circulating tumor DNA (ctDNA) in squamous cell carcinoma of the head and neck (SCCHN).
    Galot R; Machiels JH
    Cancer Treat Rev; 2020 Apr; 85():101992. PubMed ID: 32092618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Carboplatin/Paclitaxel-Based Radiochemotherapy in Locally Advanced Squamous Cell Carcinoma of Head and Neck.
    Maring S; Elsayad K; Stenner M; Rudack C; Haverkamp U; Rehkämper J; Wardelmann E; Eich HT
    Oncol Res Treat; 2018; 41(12):736-743. PubMed ID: 30419553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular Characterization of Locally Relapsed Head and Neck Cancer after Concomitant Chemoradiotherapy.
    de Roest RH; Mes SW; Poell JB; Brink A; van de Wiel MA; Bloemena E; Thai E; Poli T; Leemans CR; Brakenhoff RH
    Clin Cancer Res; 2019 Dec; 25(23):7256-7265. PubMed ID: 31439582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liquid biopsy for mutational profiling of locoregional recurrent and/or metastatic head and neck squamous cell carcinoma.
    Galot R; van Marcke C; Helaers R; Mendola A; Goebbels RM; Caignet X; Ambroise J; Wittouck K; Vikkula M; Limaye N; Machiels JH
    Oral Oncol; 2020 May; 104():104631. PubMed ID: 32169746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamics of HMBG1 (High Mobility Group Box 1) during radiochemotherapy correlate with outcome of HNSCC patients.
    Clasen K; Welz S; Faltin H; Zips D; Eckert F
    Strahlenther Onkol; 2022 Feb; 198(2):194-200. PubMed ID: 34671818
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of GeneChip, nCounter, and Real-Time PCR-Based Gene Expressions Predicting Locoregional Tumor Control after Primary and Postoperative Radiochemotherapy in Head and Neck Squamous Cell Carcinoma.
    Schmidt S; Linge A; Grosser M; Lohaus F; Gudziol V; Nowak A; Tinhofer I; Budach V; Sak A; Stuschke M; Balermpas P; Rödel C; Schäfer H; Grosu AL; Abdollahi A; Debus J; Ganswindt U; Belka C; Pigorsch S; Combs SE; Mönnich D; Zips D; Baretton GB; Buchholz F; Baumann M; Krause M; Löck S;
    J Mol Diagn; 2020 Jun; 22(6):801-810. PubMed ID: 32247864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma sICAM-1 correlates with tumor volume before primary radiochemotherapy of head and neck squamous cell carcinoma patients.
    Clasen K; Welz S; Faltin H; Zips D; Eckert F
    Radiol Oncol; 2022 Dec; 56(4):501-507. PubMed ID: 36503712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.